Niklod (Clodronate Disodium, Lidocaine Hydrochloride)

Clodronate Disodium, the active ingredient in Niklod, is a bisphosphonate presented as an injectable formulation for intramuscular use. Combined with Lidocaine Hydrochloride, a local anesthetic, the product is employed to alleviate bone‑related pain, manage hypercalcemia of malignancy, and provide local anesthesia during intramuscular procedures.

GNH USA supplies Niklod as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring quality‑controlled manufacturing and regulatory compliance for global distribution.

Niklod is used in the management of bone‑related conditions and for procedural anesthesia.

- Bone metastases pain: reduces skeletal pain associated with metastatic disease. - Hypercalcemia of malignancy: lowers elevated serum calcium levels in cancer patients. - Intramuscular local anesthesia: provides rapid numbness at the injection site for procedures.

Adverse reactions to Niklod may range from mild to severe.

Common Side Effects: - Injection site pain - Redness or swelling at the site - Mild nausea - Transient dizziness - Local irritation or itching - Low‑grade fever

Serious or Rare Side Effects: - Severe hypocalcemia - Osteonecrosis of the jaw - Anaphylactic reaction - Cardiac arrhythmias - Acute renal impairment - Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before prescribing Niklod, clinicians should consider the following precautions.

- Renal function: assess baseline kidney function and monitor during therapy. - Serum calcium: measure calcium levels before initiation and periodically thereafter. - Pregnancy: safety not established; avoid use unless benefits outweigh risks. - Lidocaine allergy: contraindicated in patients with known hypersensitivity to local anesthetics. - Concomitant bisphosphonates: avoid duplicate therapy to reduce risk of oversuppression of bone turnover. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Niklod can interact with other medicines; notable interactions are classified as follows.

Major Interactions (Avoid): - Concurrent bisphosphonates: may cause excessive inhibition of bone resorption. - Nephrotoxic agents (e.g., aminoglycosides, amphotericin B): increase risk of renal injury. - High‑dose calcium supplements: reduce clodronate absorption and efficacy. - NSAIDs: potentiate renal toxicity when combined with clodronate. - Strong CYP450 inhibitors: may elevate lidocaine plasma levels, increasing toxicity risk.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may impair clodronate uptake. - Loop diuretics: alter calcium balance, requiring monitoring. - Warfarin: monitor INR as clodronate may affect coagulation. - Other local anesthetics: cumulative systemic toxicity risk. - Corticosteroids: may increase risk of osteonecrosis of the jaw.